Four other cancer cell lines, the FGFRi-sensitive ones including NCI-H716 colon cancer cell line with FGFR2 amplification, RT112 bladder cancer cell line with FGFR3 amplification, and Hep3B liver cancer cell line with FGF19 amplification-induced FGFR4 activation, along with the FGFRi-primary resistant one (NCI-H2444 lung cancer cell line with FGFR1 amplification), were examined. The gene discussed is FGF19; the disease is lung cancer.